CN117858902A - 针对人CD16a的抗体及其变体 - Google Patents

针对人CD16a的抗体及其变体 Download PDF

Info

Publication number
CN117858902A
CN117858902A CN202280057501.6A CN202280057501A CN117858902A CN 117858902 A CN117858902 A CN 117858902A CN 202280057501 A CN202280057501 A CN 202280057501A CN 117858902 A CN117858902 A CN 117858902A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
binding portion
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280057501.6A
Other languages
English (en)
Chinese (zh)
Inventor
刘刚
李中道
赵志辉
邵翠英
刘斌
金夷
殷刘松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of CN117858902A publication Critical patent/CN117858902A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280057501.6A 2021-08-25 2022-08-25 针对人CD16a的抗体及其变体 Pending CN117858902A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021114549 2021-08-25
CNPCT/CN2021/114549 2021-08-25
PCT/CN2022/114642 WO2023025215A1 (en) 2021-08-25 2022-08-25 ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a

Publications (1)

Publication Number Publication Date
CN117858902A true CN117858902A (zh) 2024-04-09

Family

ID=85321557

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280057501.6A Pending CN117858902A (zh) 2021-08-25 2022-08-25 针对人CD16a的抗体及其变体

Country Status (6)

Country Link
US (1) US20240352128A1 (https=)
EP (1) EP4392453A4 (https=)
JP (1) JP2024532886A (https=)
KR (1) KR20240049331A (https=)
CN (1) CN117858902A (https=)
WO (1) WO2023025215A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120813603A (zh) * 2023-03-03 2025-10-17 广州百济神州生物制药有限公司 Cd16a抗体和使用方法
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
WO2024206126A1 (en) * 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
CN120025439B (zh) * 2023-11-21 2026-04-17 南京融捷康生物科技有限公司 一种抗CD16a的单域抗体及其用途
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334453D1 (de) * 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
WO2018039626A1 (en) * 2016-08-25 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human single domain antibodies targeting cd16a to mediate adcc
CN110461357A (zh) * 2017-02-28 2019-11-15 阿菲姆德股份有限公司 抗cd16a抗体与细胞因子的组合
WO2022161314A1 (zh) * 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途

Also Published As

Publication number Publication date
US20240352128A1 (en) 2024-10-24
KR20240049331A (ko) 2024-04-16
EP4392453A4 (en) 2025-10-08
WO2023025215A1 (en) 2023-03-02
EP4392453A1 (en) 2024-07-03
JP2024532886A (ja) 2024-09-10

Similar Documents

Publication Publication Date Title
JP7748933B2 (ja) 抗ｄｌｌ３キメラ抗原受容体及びその使用
WO2023025215A1 (en) ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a
WO2022068854A1 (en) Antibodies targeting human claudin 18.2 and uses thereof
US20180194862A1 (en) Bispecific binding proteins
AU2019326635B2 (en) Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
KR20220104783A (ko) Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질
WO2019210848A1 (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
CN101939337A (zh) 抗trka抗体及其衍生物
CN113527493B (zh) 一种b7-h3抗体及其应用
JP7830621B2 (ja) 抗－ｂ７－ｈ４／抗－４－１ｂｂ二重特異的抗体およびこれの用途
TW202340248A (zh) 促效性ｌｔｂｒ抗體及包含其之雙特異性抗體
CN120424213A (zh) 特异性结合pd-1的单克隆抗体及其医药用途
CN118146368A (zh) 抗ccr8抗体及其应用
WO2025077831A1 (en) Anti-il-4ra/tslp antibodies and uses thereof
EP4592315A1 (en) Antibody and use thereof in resisting tumor
HK40114235A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40114510A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
WO2024179553A1 (zh) 靶向TGFβ的融合蛋白及其应用
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
CN116888156A (zh) 非阻断性人ccr8结合剂
HK40108283A (zh) 抗b7-h4/抗4-1bb双特异性抗体及其应用
HK40065826A (zh) 抗dll3嵌合抗原受体及其用途
HK40044020A (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination